ABOUT PRODUCTS PIPELINE INVESTORS CAREERS PARTNERSHIPS EXPANDED ACCESS STOCK INFORMATION EVENTS NEWS PRESENTATIONS FINANCIAL INFORMATION ANALYST COVERAGE CONTACT US Investors Stock information Vanda’s success comes from our ability to remain consistent. That is, maintaining the same high standards throughout the entire product development process, and never losing sight of our ultimate goal–improving patients’ lives. Data as of 12/02/21 Minimum 20-minute delay Refresh quote Replication or redistribution of EDGAR Online, Inc. content is expressly prohibited without the prior written consent of EDGAR Online, Inc. EDGAR Online, Inc. shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon. Corporate Presentation Vanda Corporate Presentation - November 2021 Recent Events 2006 2007 2008 2009 2010 2011 2012 2013 2014 2015 2016 2017 2018 2019 2020 2021 11/18/21 Vanda Pharmaceuticals Inc. at Jefferies London Healthcare Conference 08:00 AM GMT 11/15/21 Vanda Pharmaceuticals Inc. at Stifel 2021 Virtual Healthcare Conference 10:00 AM EST 11/03/21 Q3 2021 Vanda Pharmaceuticals Inc. Earnings Conference Call 04:30 PM EDT 07/28/21 Q2 2021 Vanda Pharmaceuticals Inc. Earnings Conference Call 04:30 PM EDT 06/02/21 Vanda Pharmaceuticals Inc. at Jefferies Virtual Healthcare Conference 01:00 PM EDT 05/21/21 Vanda Pharmaceuticals Inc. at Oppenheimer Rare & Orphan Disease Summit 02:05 PM EDT 05/13/21 Vanda Pharmaceuticals Inc. at Bank of America 2021 Healthcare Conference 11:00 AM EDT 05/05/21 Q1 2021 Vanda Pharmaceuticals Inc. Earnings Conference Call 04:30 PM EDT 02/10/21 Q4 2020 Vanda Pharmaceuticals Inc. Earnings Conference Call 04:30 PM EST Recent News 2006 2007 2008 2009 2010 2011 2012 2013 2014 2015 2016 2017 2018 2019 2020 2021 11/10/21 Vanda Pharmaceuticals Announces Participation at November 2021 Investor Conferences 11/03/21 Vanda Pharmaceuticals Reports Third Quarter 2021 Financial Results 10/27/21 Vanda Pharmaceuticals to Announce Third Quarter 2021 Financial Results on November 3, 2021 10/14/21 Vanda Pharmaceuticals Announces Participation at Evercore ISI's Catalyst Day 09/07/21 Vanda Pharmaceuticals Announces Participation at the Citi 16th Annual BioPharma Virtual Conference 08/03/21 Vanda Pharmaceuticals Closes Enrollment In The ODYSSEY Study Comparing Tradipitant And Placebo In Hospitalized COVID-19 Pneumonia Patients 07/28/21 Vanda Pharmaceuticals Reports Second Quarter 2021 Financial Results 07/21/21 Vanda Pharmaceuticals to Announce Second Quarter 2021 Financial Results on July 28, 2021 05/12/21 Vanda Pharmaceuticals Announces Participation at Upcoming 2021 Investor Conferences 05/05/21 Vanda Pharmaceuticals Reports First Quarter 2021 Financial Results 1 2 Financial Information Quarterly Earnings 2006 2007 2008 2009 2010 2011 2012 2013 2014 2015 2016 2017 2018 2019 2020 2021 11/04/21 10-Q-Quarterly report which provides a continuing view of a company's financial position PDF 88.0KB 07/29/21 10-Q-Quarterly report which provides a continuing view of a company's financial position PDF 88.0KB 05/06/21 10-Q-Quarterly report which provides a continuing view of a company's financial position PDF 88.0KB 02/11/21 10-K-Annual report which provides a comprehensive overview of the company for the past year PDF 88.0KB Financial Information SEC Filings 2006 2007 2008 2009 2010 2011 2012 2013 2014 2015 2016 2017 2018 2019 2020 2021 12/02/21 4-Statement of changes in beneficial ownership of securities PDF 88.0KB 11/04/21 10-Q-Quarterly report which provides a continuing view of a company's financial position PDF 88.0KB 11/03/21 8-K-Report of unscheduled material events or corporate event PDF 88.0KB 10/08/21 8-K-Report of unscheduled material events or corporate event PDF 88.0KB 09/17/21 4-Statement of changes in beneficial ownership of securities PDF 88.0KB 09/13/21 4-Statement of changes in beneficial ownership of securities PDF 88.0KB 08/23/21 4-Statement of changes in beneficial ownership of securities PDF 88.0KB 08/17/21 4-Statement of changes in beneficial ownership of securities PDF 88.0KB 07/30/21 4-Statement of changes in beneficial ownership of securities PDF 88.0KB 07/29/21 10-Q-Quarterly report which provides a continuing view of a company's financial position PDF 88.0KB 1 2 3 4 5 6 Corporate Governance Vanda is developing important new medicines to improve the lives of patients. We use new technologies, including genetics and genomics, to inform our drug discovery, our clinical trials, and our commercial positioning of our compounds. We are working to advance the science of developing new medicines and to use novel approaches to deliver these new medicines to patients. Our CEO, Mihales Polymeropoulos, MD, founded Vanda in 2003. Previously, he founded and ran the Novartis global Pharmacogenetics department, one of the industry leaders. Prior to that he worked for many years at the National Institute of Mental Health and the National Human Genome Research Institute, where he did pioneering work in gene mapping. He founded Vanda in partnership with Care Capital LLC, the prominent biopharmaceuticals-focused investment firm, and Bio*One Capital, an investment arm of the Singapore government with a focus on new biomedical enterprises. Vanda has assembled an experienced team and a stable of clinical stage compounds to deliver on its vision. LEARN MORE Analyst Coverage Firm Bank of America Jefferies Analyst Olivia Brayer Chris Howerton, Ph.D. Vanda Pharmaceuticals Inc. is followed by the analysts listed above. Please note that any opinions, estimates or forecasts regarding Vanda Pharmaceuticals Inc.'s performance made by these analysts are theirs alone and do not represent opinions, forecasts or predictions of Vanda Pharmaceuticals Inc. or its management. Vanda Pharmaceuticals Inc. does not by its reference above or distribution imply its endorsement of or concurrence with such information, conclusions or recommendations. Contact Us Primary IR Contact For members of the press or investor community who wish to obtain more information about Vanda, please contact: Kevin Moran Senior Vice President, Chief Financial Officer and Treasurer Vanda Pharmaceuticals Inc. (202) 734-3400 pr@vandapharma.com Information Request To request information, please fill out and submit the form below. *Required fields First Name* Last Name* Title Organization Investor Type Address 1 Address 2 City State Zip Code Country Phone Fax E-mail* Questions/Comments choose your options for e-mail notification Vanda Pharmaceuticals, Inc. SEC Alert Vanda Pharmaceuticals, Inc. Report Alert Vanda Pharmaceuticals, Inc. Presentation Alert Vanda Pharmaceuticals, Inc. Calendar Alert Vanda Pharmaceuticals, Inc. News Alert Vanda Pharmaceuticals, Inc. End-of-Day Stock Quote Alert Vanda Pharmaceuticals, Inc. Annual Report Alert ABOUT Company Profile Corporate Officers Board of Directors Corporate Governance PRODUCTS HETLIOZ® Fanapt® PIPELINE Clinical Development Pipeline INVESTORS Stock Information News Presentations Financial Information Corporate Governance Analyst Coverage Contact Us CAREERS Career Search TERMS & CONDITIONS PRIVACY NOTICE COPYRIGHT © 2021 VANDA PHARMACEUTICALS